BANHAM、孟生及劉志敏為獨立非執行董事。 第 2 頁 共 2 頁 v 1.1.1 第 1 頁 共 2 頁 v 1.1.1 | 代扣所得稅信息 | | | --- | --- | | 股息所涉及的代扣所得稅 | 不適用 | | 發行人所發行上市權證/可轉換債券的相關信息 | | | 發行人所發行上市權證/可轉換債券 | 不適用 | | 其他信息 | | | 其他信息 | 不適用 | | 發行人董事 | | | 截至本公告刊發日期，本公司的董事如下：何超瓊、William Joseph HORNBUCKLE、John M. MCMANUS、劉珍伲及馮小峰為執行 | 董事；Daniel J. TAYLOR、Ayesha Khanna MOLINO及Jonathan S. HALKYARD為非執行董事；及黃林詩韻、Russell Francis | EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | ...

美高梅中国(02282)发布公告，于2025年8月20日该公司注销500万股已购回股份。 ...

智通财经APP讯，美高梅中国(02282)发布公告，于2025年8月20日该公司注销500万股已购回股份。 ...

格隆汇8月20日丨美高梅中国(02282.HK)发布公告，2025年8月20日，公司注销500万股回购的股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 美高梅中國控股有限公司(於開曼群島註冊成立的有限公司) 呈交日期： 2025年8月20日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02282 | 說明 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | 已發行股份總數 | | 事件 | | 已發行股份（不包括庫存股 ...

Core Points - The Shanghai Composite Index opened lower but rose throughout the day, while the Chinese Gaming Services Index (CESG10) fell by 1.53% to 3254.02 points with a trading volume of 919 million [1] - Over the past month, the Chinese Gaming Services Index has increased by 1.92%, by 28.91% over the last three months, and by 21.04% year-to-date [1] - The Chinese Gaming Services Index is compiled by China Securities Index Co., Ltd. on behalf of China Securities Trading Services Co., Ltd., reflecting the overall performance of the top ten gaming securities listed on the Hong Kong Stock Exchange [1] - The index is based on a reference date of March 4, 2011, with a base point of 3000.0 [1] - The index's holdings are entirely composed of securities from the Hong Kong Stock Exchange, with 100% allocation to the consumer discretionary sector [1]

Summary of Key Points Core Viewpoint - On August 14, 10 Hong Kong-listed companies conducted share buybacks totaling 4.44 million shares and an amount of 46.21 million HKD, indicating a trend of companies returning capital to shareholders through buybacks [1][2]. Group 1: Buyback Details - Hang Seng Bank repurchased 200,000 shares for 22.87 million HKD, with a highest price of 115.40 HKD and a lowest price of 113.60 HKD, accumulating a total buyback amount of 228 million HKD for the year [1][2]. - MGM China repurchased 1 million shares for 16.18 million HKD, with a highest price of 16.25 HKD and a lowest price of 16.10 HKD, totaling 103 million HKD in buybacks for the year [1][2]. - FIH Mobile (富智康集团) repurchased 208,000 shares for 3.11 million HKD, with a highest price of 15.02 HKD and a lowest price of 14.91 HKD, accumulating 37.53 million HKD in buybacks for the year [1][2]. Group 2: Notable Buyback Activities - The largest buyback amount on August 14 was by Hang Seng Bank at 22.87 million HKD, followed by MGM China at 16.18 million HKD [1][2]. - In terms of share quantity, the highest number of shares repurchased was by I.T Limited (互太纺织) with 2 million shares, followed by MGM China and HYPEBEAST with 1 million and 935,200 shares respectively [1][2]. - I.T Limited's buyback on this date marked its first buyback of the year, while Hang Seng Bank has conducted multiple buybacks totaling 228 million HKD for the year [2].

每经AI快讯，数据显示，8月14日，共10只港股获公司回购，2只个股回购金额超千万港元。其中，恒 生银行、美高梅中国、富智康集团回购金额最大，分别获公司回购2286.7万港元、1618.07万港元、 311.04万港元。截至8月14日，今年已有218只港股获公司回购，43只个股年内累计回购金额超亿港元。 其中，腾讯控股、汇丰控股、友邦保险年内累计回购金额最大，分别获公司回购400.43亿港元、222.01 亿港元、176.93亿港元。 ...

Group 1 - The article reports on share buybacks conducted by several companies on August 14, 2025, with Hang Seng Bank having the largest buyback amount of 22.867 million HKD for 200,000 shares [1][2] - The total number of shares repurchased by each company varies, with MGM China repurchasing 1,000,000 shares for 16.1807 million HKD, and FIH Mobile repurchasing 208,000 shares for 3.1104 million HKD [2] - The cumulative buyback amounts for the year show that Hang Seng Bank has repurchased a total of 2 million shares, representing 0.106% of its total share capital [2] Group 2 - The buyback activity indicates a trend among companies to return capital to shareholders, with notable participation from firms like HYPEBEAST and North Forest Holdings, which repurchased 935,200 and 9,600 shares respectively [2] - The buyback amounts and percentages of total share capital for other companies include FIH Mobile at 0.401%, and Yanzheng Technology at 1.082%, indicating varying levels of commitment to share repurchase programs [2] - The data reflects a broader strategy among these companies to enhance shareholder value through share buybacks, which can signal confidence in their financial health [1][2]

Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]